Pipeline

EE-CSWS

Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep (EE-CSWS)

Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep (EE-CSWS) is a rare pediatric epilepsy. Typical onset occurs between ages 2 and 4 years old with seizures occurring infrequently. Diagnosis of EE-CSWS is based on a unique electroencephalographic (EEG) pattern for electrical status epilepticus in sleep (ESES), together with cognitive stagnation and regression.

Impacts less than 2% of the children living with epilepsy worldwide. There is currently no approved treatment for the disorder.

NBI-827104: An Investigational Therapy for EE-CSWS

Neurocrine Biosciences acquired the exclusive rights to NBI-827104 from Idorsia Ltd. NBI-827104 is a potent, selective, orally active and brain penetrating T-type calcium channel blocker.

Neurocrine Biosciences has received orphan drug and rare pediatric disease designations from the U.S. Food and Drug Administration (FDA) for NBI-827104 in EE-CSWS.

Clinical Trials: EE-CSWS

Neurocrine Biosciences is conducting the STEAMBOAT™ study, a Phase 2 study to assess the efficacy, safety, tolerability, and pharmacokinetics of NBI-827104 in pediatric patients with EE-CSWS. For more information about this Phase 2 study of NBI-827104, please visit SteamboatStudy.com or ClinicalTrials.gov.